ASCO 2022 on the rEECur Trial: High-Dose Ifosfamide as a SoC for Recurrent and Primary Refractory Ewing Sarcoma

By ecancer FEATURING Martin Mccabe
By ecancer FEATURING Martin Mccabe
28 views
June 24, 2022
Comments 0
Login to view comments. Click here to Login